Meet Profil at the ADA Scientific Sessions

About the ADA Scientific Sessions and the ADA Forum

Like every year, Profil Germany will be present at the ADA Scientific Sessions. We will have numerous posters again as well as some talks. Of course we look forward to this exciting event very much. 

We are proud that for the 2nd time, Profil Germany will be a Supporting Sponsor of the ADA Forum, the yearly event hosted by TCOYD and The diaTribe Foundation in conjunction with the ADA Scientific Sessions. The event will be held at the Ritz-Carlton New Orleans, Lafayette Room 921 Canal St on June 13th, 2016 starting at 6:30pm. Food and drinks will be served and as always there will be exciting high calibre scientific talks in a relaxed atmosphere. Learn more about the event here. 

Here is a list of our scientific contributions at the ADA Scientific Sessions 

Oral Presentations

• 294-OR / 294 - Ultra-Rapid BioChaperone_^® Lispro Ameliorates Postprandial Blood Glucose (PPG) Control Compared with Humalog in Subjects with Type 1 Diabetes Mellitus

• 295-OR / 295 - BioChaperone® Combo (BC Combo) Improves Postprandial Glycemia vs. Humalog® Mix 75/25™ (HMx) in People with Type 1 Diabetes Mellitus (T1DM)

Poster Presentations

• 969-P / 969 - Greater Early Glucose-Lowering Effect of Faster-Acting Insulin Aspart Is Observed Consistently from Day-to-Day

• 929-P / 929 - Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes

• 936-P / 936 - Double Dose (DD) of Basal Insulin Peglispro (BIL) vs. Glargine (GL) Results in Markedly Lower Incidence of Hypoglycemia in Patients with T2D: IMAGINE 8

• 1012-P / 1012 - The Effects of Semaglutide on ß-cell Function in Subjects with Type 2 Diabetes

• 956-P / 956 - Solumarv (SOLU), a Regular Human Insulin, and Isomarv (ISO), a NPH-Insulin Preparation, Show Bioequivalence (BE) to EU-Marketed Insulins

• 1018-P / 1018 - Efficacy and Safety of LixiLan vs. Insulin Glargine According to Baseline Characteristics in Patients with Type 2 Diabetes from the LixiLan-L Trial

• 942-P / 942 - Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)

• 1892-P / 1892 - Dopamine Agonists Reverse Hyperglycemia in Streptozotocin-induced Diabetic Mice

• 100-LB / 100 - Technosphere Insulin Inhalation Powder (TI) Displays Earlier Onset and Shorter Duration than Insulin Lispro (Lispro)

• 102-LB / 102 - Within-Subject Variability of Insulin Exposure and Metabolic Activity following Replicate Doses of Technosphere® Insulin Inhalation Powder (TI) in Patients with T1DM

• 908-P / 908 - Glycemic Benefits of a Long-Term Implantable Glucose Sensor in the PRECISE Study

• 982-P / 982 - Insulin Pharmacodynamics and Outcomes during Home Use of Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes

• 1189-P / 1189 - Safety and Efficacy of BI 187004, a Selective 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) Inhibitor after 4 Weeks of Treatment in Patients with Type 2 Diabetes

Other things you should know about the ADA Scientific Sessions

• You can meet with a Profil representative at the occasion of the ADA Scientific Sessions to discuss your research or product developments. Just click here and request a meeting with us or fill out the form on the right or send an email to lars.bochmann@profil.com.

• After the publication embargo is lifted, you can download some of our posters here. 

• Are you at the Bio International Convention in San Francisco just before the ADA? Then request a meeting with us and come to our booth (Booth 905 - Germany Pavilion). You may fill out the form on the right to request a meeting.